Study Confirms Link Between Analgesic Use, Ovarian Cancer
Case-control study shows any analgesic, aspirin use may reduce risk of ovarian cancer.
Ovarian Cancer
Treatment at High-Volume Hospitals Results in Lower Death Rates for Ovarian Cancer
Patients with ovarian cancer treated at high-volume hospitals have lower mortality primarily because the hospitals have the ability to rescue patients when complications arise, not because of lower complication rates.
Symptom Survey Can Help Identify Symptoms of Ovarian Cancer
Completing a simple symptom survey can effectively identify women with symptoms that may indicate ovarian cancer.
ESA Increases VTE Risk but Does Not Affect OS in Women Administered Bevacizumab for Ovarian Cancer
Erythropoietin stimulating agents and granulocyte colony stimulating factor do not affect OS among patients with ovarian cancer who receive bevacizumab plus chemotherapy, but ESA is associated with a significantly-elevated risk of venous thrombotic events.
Patupilone Does Not Improve OS in Platinum-Refractory Ovarian Cancer
Patupilone did not significantly improve overall survival compared with pegylated liposomal doxorubicin in patients with platinum-refractory or -resistant ovarian cancer.
Ovarian Cancer: To Screen or Not to Screen?
Screening healthy women for ovarian cancer may do more harm than good, but is it a risk some patients may be willing to take for peace of mind?
USPSTF Discourages Screening Asymptomatic Women for Ovarian Cancer
The United States Preventive Services Task Force has reaffirmed its 2004 recommendation statement against routine screening of asymptomatic women for ovarian cancer.
Frequent Ovarian Cancer Screening Does Not Cause Sustained Psychological Harm
Frequent ovarian cancer screening does not increase anxiety or depression, but can increase the risk of a woman dropping out of the screening program soon after an abnormal test result.
Type 2 Diabetes Mellitus Does Not Up Epithelial Ovarian Cancer Risk
According to a study, type 2 diabetes mellitus is not associated with an increased risk of epithelial ovarian cancer.
LRP1B Contributes to Chemoresistance in HGSC Ovarian Cancer
LRP1B expression in women with high-grade serous cancer contributes to chemotherapy resistance.
- Loading...
Loading...
Loading... 
Loading...